샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757611

RWE(Real World Evidence) 애플리케이션용 게놈 데이터세트 시장

Genomic Data Set for Real World Evidence (RWE) Applications
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 381 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 RWE(Real World Evidence) 애플리케이션용 게놈 데이터세트 시장은 2030년까지 12억 달러에 달할 전망

2024년에 5억 3,330만 달러로 추정되는 세계의 RWE(Real World Evidence) 애플리케이션용 게놈 데이터세트 시장은 분석 기간인 2024-2030년에 CAGR 15.1%로 성장하며, 2030년에는 12억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 유전자 DNA 데이터는 CAGR 17.3%를 기록하며, 분석 기간 종료시에는 5억 4,740만 달러에 달할 것으로 예측됩니다. 전사체 RNA 데이터 분야의 성장률은 분석 기간 중 CAGR 12.8%로 추정됩니다.

미국 시장은 1억 4,530만 달러로 추정, 중국은 CAGR 20.4%로 성장할 것으로 예측

미국의 RWE(Real World Evidence) 애플리케이션용 게놈 데이터세트 시장은 2024년에 1억 4,530만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR 20.4%를 견인하며, 2030년에는 2억 7,300만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 10.9%와 13.7%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.1%로 성장할 것으로 예측됩니다.

세계의 "RWE(Real World Evidence) 애플리케이션용 게놈 데이터세트" 시장 - 주요 동향과 촉진요인 정리

유전체 데이터세트가 실제 증거 기반을 어떻게 변화시키고 있는가?

리얼월드에비던스(RWE) 프레임워크에서 유전체 데이터세트의 적용은 생명과학 산업이 증거 생성, 규제 당국의 의사결정, 임상 전략에 접근하는 방식을 빠르게 변화시키고 있습니다. 기존에는 RGlobal Industry Analyst가 전자건강기록(EHR), 보험 청구, 환자 등록, 건강 조사 등의 정보 소스에서 얻은 관찰 데이터에 의존해 왔습니다. 그러나 유전체 시퀀싱, 특히 차세대 염기서열 분석(NGS)의 비약적인 성장으로 방대한 유전체 데이터세트가 RGlobal Industry Analysts 플랫폼에 통합되어 보다 생물학적 근거에 기반한 정확성을 중시하는 헬스케어 인사이트의 기반이 구축되고 있습니다. 구축되고 있습니다. 이러한 변화는 유전적 변이에 기반한 질병 병인, 환자 계층화, 치료 효과 및 결과에 대한 더 깊은 이해를 가능하게 합니다. 예를 들어 Genome RGlobal Industry Analysts는 약물 반응, 부작용, 질병 진행을 예측하는 바이오마커를 식별하는 데 도움을 주고 있습니다. 바이오 제약사 및 연구기관들은 UK Biobank, All of Us Research Program, Genomics England 등의 대규모 집단 코호트에서 연계된 유전체 데이터와 표현형 데이터를 활용하여 실용적인 증거를 대규모로 도출하고자 노력하고 있습니다. 또한 전 세계 의료 시스템이 디지털화되고 정밀의료 모델이 채택됨에 따라 종합적인 유전체 데이터세트를 실생활에서 사용함으로써 관찰 연구에서 전례 없는 잠재력을 발휘하고, 표적 치료법 개발을 가속화하며, 시장 전반의 규제 및 상환 전략에 대한 지침이 되고 있습니다.

유전체 RWE 활용을 가능하게 하는 기술 및 인프라의 발전은?

유전체 데이터를 RGlobal Industry Analysts 용도에 통합하는 것은 인프라 준비, 기술 상호운용성 및 고급 분석에 크게 의존합니다. 핵심은 전체 유전체, 전체 엑솜, 표적 염기서열 등 광범위한 유전체 프로파일을 생성하는 고처리량 시퀀싱 플랫폼입니다. 이러한 유전체 데이터세트는 프라이버시를 보호하는 레코드 연결 기술과 이종 데이터의 저장 및 조정을 위해 설계된 클라우드 기반 데이터 레이크를 사용하여 종단적 환자 데이터와 연결됩니다. 클라우드 인프라, 특히 AWS, Google Cloud, Microsoft Azure와 같은 공급자와의 제휴를 통해 유전체 파이프라인에 대한 확장 가능하고 안전한 접근이 가능합니다. 생물정보학 툴와 인공지능 알고리즘은 이 복잡한 데이터 마이닝의 핵심으로, 유전형-표현형 상관관계 식별, 집단 특이적 변이 분석, 분산된 데이터 소스에서 실시간 증거를 생성할 수 있게 해줍니다. 또한 연구기관은 기밀성이 높은 유전체 데이터를 보호된 환경 외부로 이동하지 않고도 RGlobal Industry Analysts의 연구에 협력할 수 있는 페더레이션형 학습 모델을 지지하고 있습니다. 유전체 정보를 위한 FHIR Genomics 및 OMOP CDM 확장 등의 상호운용성 표준은 이러한 데이터를 EHR, 임상시험, 관찰 연구에 일관되게 통합할 수 있도록 하는 데 필수적입니다. 기관 차원에서는 유전체 데이터 웨어하우스와 동의 관리 프레임워크가 연구 및 정책 수립을 위한 2차 활용을 촉진하면서 환자의 프라이버시를 보장하기 위해 도입되고 있습니다. 이러한 툴의 고도화는 RWE로 달성할 수 있는 것의 한계를 뛰어넘어 유전체학을 미래 지향적인 헬스케어 시스템의 기본 계층으로 자리 매김하고 있습니다.

헬스케어 및 생명과학 분야에서 GenomeRGlobal Industry Analysts를 최종사용자들은 어떻게 활용하고 있는가?

RGlobal Industry Analysts 용도에서 유전체 데이터세트의 채택은 제약사, 지불자, 프로바이더, 규제 당국, 학술기관 등 다양한 최종사용자로 확대되고 있습니다. 제약사들은 유전체RGlobal Industry Analysts를 활용하여 표적 환자 모집, 적응증 모델, 시판 후 안전성 모니터링을 통해 임상시험 설계를 최적화하고 있습니다. 특정 유전자 변이가 실제 다양한 환자군의 치료 반응에 어떤 영향을 미치는지 분석함으로써 기업은 미충족 수요를 더 정확하게 파악하고, 관련 평가변수를 선택하며, 치료법을 더 정확하게 조정할 수 있습니다. 보험사들은 가치 기반 계약, 적용 기준, 정밀한 처방 관리와 관련된 의사결정을 지원하기 위해 유전체RGlobal Industry Analysts에 의존하기 시작했습니다. 병원과 의료 시스템도 특히 종양학, 희귀질환, 약물유전체학 분야에서 진단 정확도를 높이고 치료 경로를 맞춤화하기 위해 유전체 데이터를 임상 의사결정 지원 툴에 통합하고 있으며, FDA와 EMA와 같은 규제 당국도 유전체 정보를 기반으로 한 RGlobal Industry Analysts를 채택하여 추가 승인, 첨부문서 확대, 이미 시판 중인 의약품의 위험-편익 평가를 지원하고 있습니다. 또한 학계 연구자들은 이러한 데이터세트를 실제 유전자와 환경의 상호작용 및 집단별 건강 격차 연구에 적용하고 있습니다. 실제 유전체학은 감염병 변이 감시, 백신 효과 평가 등 공중보건 유전체학 연구에도 활용되고 있습니다. 이해관계자의 요구, 기술적 준비, 정책의 진화가 결합되면서 유전체 RG를 보건의료의 전 과정에 통합하는 제도적 노력이 확산되고 있습니다.

유전체 RGlobal Analysts 시장의 성장을 가속하는 주요 요인은?

리얼월드에비던스(RWE) 용도를 위한 유전체 데이터세트 시장의 성장은 기술 발전, 헬스케어 모델 전환, 데이터 접근성, 최종사용자 인센티브와 관련된 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 유전체 염기서열 분석 비용의 급격한 하락으로 다양한 환자 코호트의 대규모 염기서열 분석이 가능해져 보다 대표적이고 종합적인 RGlobal Industry Analysts 연구가 가능해졌습니다. 둘째, 가치 기반 치료와 정밀의료 모델의 부상으로 인해, 더 나은 결과를 더 낮은 비용으로 지원하기 위해 유전자 데이터를 통합한 개인화된 증거에 대한 강력한 수요가 발생하고 있습니다. 셋째, 규제 당국이 유전체 RGlobal Industry Analysts를 시판 후 조사, 조기 승인 및 약물 재사용을 위한 효과적인 증거 스트림으로 인식하고 있으며, 이는 제약사가 유전체으로 강화된 실제 임상시험에 투자할 수 있는 분명한 인센티브가 되고 있습니다. 또 다른 큰 원동력은 유전체 프로파일과 평생 건강 기록을 연결하고 관찰 분석을 위한 풍부한 데이터 환경을 제공하는 종단적 바이오뱅크와 국가 유전체 프로그램의 확산입니다. 또한 특히 종양이나 희귀질환과 같은 고비용 영역에서 유전체 정보 기반 이용 관리에 대한 지불자의 관심이 높아지고 있습니다. 상호 운용 가능한 데이터 표준과 동의에 기반한 데이터 공유 프레임워크의 개발도 실제 연구 환경에서 유전체 RGGlobal Industry Analysts의 통합과 활용을 용이하게 하고 있습니다. 또한 AI를 활용한 분석 플랫폼은 실제 집단의 멀티오믹 데이터를 통해 보다 빠른 인사이트와 보다 역동적인 가설 검증을 가능하게 합니다. 마지막으로 하이테크 기업, 의료 시스템, 생명과학 기업 간의 파트너십이 전 세계에서 확대되면서 Genome RGlobal Industry Analysts 용도의 상용화와 실용화가 가속화되고 있습니다. 이러한 요소들이 결합되어 정밀의료 시대의 실제 증거 생성의 기준을 재정의할 준비가 되어 있는 견고하고 성장하는 세계 시장을 주도하고 있습니다.

부문

데이터 유형(유전자 DNA 데이터, 전사체 RNA 데이터, 프로테옴 단백질 질데이터, 대사물 데이터), 용도(종양학 용도, 심장혈관계 용도, 신경학 용도, 면역학 용도, 기타 용도), 최종 용도(바이오의약품 최종 용도, 기타 최종 용도)

조사 대상 기업의 예(주목 42사)

  • 23andMe
  • Aetion Inc.
  • BC Platforms
  • Caris Life Sciences
  • Cegedim Health Data
  • Citeline
  • Clarify Health
  • Cognizant
  • ConcertAI
  • Cytel Inc.
  • Datavant
  • Epigene Labs
  • Flatiron Health
  • Foundation Medicine, Inc.
  • Genuity Science
  • Guardant Health
  • HealthVerity, Inc.
  • Helix
  • ICarbonX
  • Illumina, Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.03

Global Genomic Data Set for Real World Evidence (RWE) Applications Market to Reach US$1.2 Billion by 2030

The global market for Genomic Data Set for Real World Evidence (RWE) Applications estimated at US$533.3 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 15.1% over the analysis period 2024-2030. Genetic DNA Data, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$547.4 Million by the end of the analysis period. Growth in the Transcriptome RNA Data segment is estimated at 12.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$145.3 Million While China is Forecast to Grow at 20.4% CAGR

The Genomic Data Set for Real World Evidence (RWE) Applications market in the U.S. is estimated at US$145.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$273.0 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.9% and 13.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global "Genomic Data Set for Real World Evidence (RWE) Applications" Market - Key Trends & Drivers Summarized

How Are Genomic Data Sets Transforming the Foundation of Real World Evidence?

The application of genomic data sets in Real World Evidence (RWE) frameworks is rapidly reshaping how the life sciences industry approaches evidence generation, regulatory decision-making, and clinical strategy. Traditionally, RWE relied on observational data from sources such as electronic health records (EHRs), insurance claims, patient registries, and health surveys. However, with the exponential growth of genomic sequencing, especially next-generation sequencing (NGS), vast genomic data sets are being integrated into RWE platforms to create a more biologically anchored, precision-driven foundation for healthcare insights. This shift enables a deeper understanding of disease etiology, patient stratification, treatment efficacy, and outcomes based on genetic variability. For example, genomic RWE is becoming instrumental in identifying biomarkers predictive of drug response, adverse events, and disease progression-information critical for both drug development and clinical practice. Biopharma companies and research institutions are increasingly leveraging linked genomic and phenotypic data from large population cohorts, such as those curated by the UK Biobank, All of Us Research Program, and Genomics England, to derive actionable evidence at scale. Moreover, as global health systems digitize and adopt precision medicine models, the use of comprehensive genomic data sets in real-world contexts is unlocking unprecedented potential in observational research, accelerating the development of targeted therapies, and guiding regulatory and reimbursement strategies across markets.

What Technological and Infrastructure Advances Are Enabling the Use of Genomic RWE?

The integration of genomic data into RWE applications is heavily dependent on infrastructure readiness, technological interoperability, and advanced analytics. At the core are high-throughput sequencing platforms that generate extensive genomic profiles, including whole-genome, whole-exome, and targeted sequencing. These genomic data sets are then linked with longitudinal patient data using privacy-preserving record linkage technologies and cloud-based data lakes designed to store and harmonize heterogeneous data types. Cloud infrastructure, particularly through partnerships with providers like AWS, Google Cloud, and Microsoft Azure, allows scalable and secure access to genomic RWE pipelines. Bioinformatics tools and artificial intelligence algorithms are central to mining this complex data, enabling identification of genotype-phenotype correlations, population-specific variant analysis, and real-time evidence generation from decentralized data sources. Federated learning models are also gaining traction, allowing institutions to collaborate on RWE studies without moving sensitive genomic data outside protected environments. Interoperability standards such as FHIR Genomics and OMOP CDM extensions for genomic information are essential for ensuring that these data can be consistently integrated into EHRs, clinical trials, and observational studies. At the institutional level, genomic data warehouses and consent management frameworks are being deployed to ensure patient privacy while facilitating secondary use for research and policy-making. The sophistication of these tools is pushing the boundaries of what can be achieved in RWE, positioning genomics as a foundational layer of future-ready healthcare systems.

How Are End Users Adopting Genomic RWE Across Healthcare and Life Sciences?

The adoption of genomic data sets in RWE applications is expanding across a broad spectrum of end users, including pharmaceutical companies, payers, providers, regulators, and academic institutions. In drug development, biopharma companies are utilizing genomic RWE to optimize clinical trial design through targeted patient recruitment, adaptive trial models, and post-market safety monitoring. By analyzing how specific genetic variants influence treatment responses in diverse, real-world populations, companies can better identify unmet needs, select relevant endpoints, and tailor therapies more precisely. In the payer space, insurers are beginning to rely on genomic RWE to support decisions around value-based contracting, coverage criteria, and precision formulary management. Hospitals and health systems are also incorporating genomic data into clinical decision support tools to enhance diagnostic accuracy and personalize care pathways, particularly in oncology, rare diseases, and pharmacogenomics. Regulators such as the FDA and EMA are embracing genomically-informed RWE to support supplemental approvals, label expansions, and risk-benefit assessments of drugs already in the market. Furthermore, academic researchers are applying these data sets to study real-world gene-environment interactions and population-specific health disparities. Real-world genomics is also being used in public health genomics initiatives, such as surveillance of infectious disease mutations and assessment of vaccine effectiveness. The convergence of stakeholder demand, technological readiness, and policy evolution is driving widespread institutional commitment to embedding genomic RWE across the healthcare continuum.

What Are the Main Drivers Fueling Growth in the Genomic RWE Market?

The growth in the genomic data set for Real World Evidence (RWE) applications market is driven by several factors related to technological advances, shifting healthcare models, data accessibility, and end-user incentives. First, the dramatic reduction in the cost of genomic sequencing has made it feasible to conduct large-scale sequencing of diverse patient cohorts, enabling more representative and inclusive RWE studies. Second, the rise of value-based care and precision medicine models is creating a strong demand for individualized evidence that incorporates genetic data to support better outcomes at lower costs. Third, regulatory bodies are increasingly recognizing genomic RWE as a valid evidence stream for post-market surveillance, accelerated approvals, and drug repurposing efforts, providing a clear incentive for pharmaceutical firms to invest in genomically-enhanced real-world studies. Another major driver is the proliferation of longitudinal bio-banks and national genomics programs that link genomic profiles with lifetime health records, offering rich data environments for observational analysis. Additionally, payer interest in genomics-informed utilization management is growing, particularly in high-cost areas like oncology and rare diseases. The development of interoperable data standards and consent-based data sharing frameworks is also facilitating easier integration and use of genomic RWE in real-world research environments. Furthermore, AI-powered analytics platforms are enabling faster insights and more dynamic hypothesis testing using multi-omic data in real-world populations. Finally, the global expansion of partnerships between tech firms, health systems, and life sciences players is accelerating the commercialization and operationalization of genomic RWE applications. Together, these factors are driving a robust and expanding global market poised to redefine the standards of real-world evidence generation in the precision medicine era.

SCOPE OF STUDY:

The report analyzes the Genomic Data Set for Real World Evidence (RWE) Applications market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Data Type (Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data, Metabolite Data); Application (Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application, Other Applications); End-Use (Biopharma End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • 23andMe
  • Aetion Inc.
  • BC Platforms
  • Caris Life Sciences
  • Cegedim Health Data
  • Citeline
  • Clarify Health
  • Cognizant
  • ConcertAI
  • Cytel Inc.
  • Datavant
  • Epigene Labs
  • Flatiron Health
  • Foundation Medicine, Inc.
  • Genuity Science
  • Guardant Health
  • HealthVerity, Inc.
  • Helix
  • ICarbonX
  • Illumina, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Genomic Data Set for Real World Evidence (RWE) Applications - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Emphasis on Personalized Therapies Drives Use of Genomic RWE for Targeted Interventions
    • Integration of Genomic and Clinical Data Sets Strengthens Business Case for Advanced Evidence Models
    • Regulatory Support for RWE in Drug Approvals Throws Spotlight on Genomic Data Validity
    • Growth in Population Genomics Projects Expands Scope and Depth of Data Repositories
    • Adoption of Genomic RWE in Post-Marketing Surveillance Accelerates Market Expansion
    • Partnerships Between Biobanks, Payers, and Pharma Drive Standardization of Genomic Evidence
    • Advances in Data Curation and Interoperability Tools Enhance Accessibility of Genomic Insights
    • Use of AI and Machine Learning Propels Predictive Modeling Based on Genomic RWE
    • Patient Advocacy and Data Ownership Trends Create Demand for Transparent Usage Models
    • Healthcare Systems Shift Toward Outcome-Based Payments Supports Integration of RWE
    • Concerns Over Genomic Data Privacy and Security Shape Governance Frameworks and Partnerships
    • Global Health Initiatives and Rare Disease Research Sustain Investment in RWE-Ready Genomic Data
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Genomic Data Set for Real World Evidence (RWE) Applications Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Genetic DNA Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Genetic DNA Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Genetic DNA Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Transcriptome RNA Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Transcriptome RNA Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Transcriptome RNA Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Proteome Protein Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Proteome Protein Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Proteome Protein Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Metabolite Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Metabolite Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Metabolite Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Biopharma End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Biopharma End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Biopharma End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cardiovascular Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Immunology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Immunology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Immunology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • JAPAN
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • CHINA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • EUROPE
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • FRANCE
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • GERMANY
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • INDIA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • AFRICA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제